Mabpharm (HKSE:02181) Preferred Dividends : HK$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Mabpharm Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Mabpharm's preferred dividends for the six months ended in Dec. 2023 was HK$0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.00 Mil.

Mabpharm Preferred Dividends Historical Data

The historical data trend for Mabpharm's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabpharm Preferred Dividends Chart

Mabpharm Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Preferred Dividends

Get a 7-Day Free Trial

Mabpharm Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Preferred Dividends	Get a 7-Day Free Trial								-	-	-	-	-

Mabpharm Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Mabpharm (HKSE:02181) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.00 Mil.

Mabpharm (HKSE:02181) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabpharm Ltd (HKSE:02181) » Definitions » Preferred Dividends

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300

Website

http://www.mabpharm.cn

Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).

Executives

Guo Jianjun	2307 Founder of a discretionary trust who can infl
Asia Mabtech Limited
Asia Pacific Immunotech Venture Limited
Guo Family (ptc) Limited
Fortune-healthy Investment Limited
Link Best Capital Limited
Cdh Fund V, L.p.
Cdh Mabtech Limited
Cdh V Holdings Company Limited
China Diamond Holdings Company Limited
China Diamond Holdings V Limited

Mabpharm (HKSE:02181) Headlines

No Headlines